Virax Biolabs Group Limited Ordinary Shares · NASDAQ
$2.90-0.10 (-3.33%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Virax Biolabs Group Limited Ordinary Shares, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $1.00 to $1.00, so the covering firms are broadly aligned. The average target of $1.00 sits 66% below the current $2.90. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.75 next quarter toward $-6.00 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Virax Biolabs Group Limited Ordinary Shares.
As of Aug, 1 of 1 firms rate VRAX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VRAX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.75
Range $-1.75 – $-1.75 · 1 analysts
Next period, 1 analysts expect Virax Biolabs Group Limited Ordinary Shares to earn $-1.75 a share (range $-1.75 – $-1.75), versus — a year earlier. Full-year consensus is $-6.00, growing to $-6.00 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $4.0K, rising to $4.0K next year.
Top analysts covering Virax Biolabs Group Limited Ordinary Shares
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRAX.
#1
Yi Chen
HC Wainwright & Co. · Rank #276
Buy
$1.00-65.5% to target
Overall win rate
33%
+ Follow
VRAX stock forecast FAQ
What is VRAX's average 12-month price target?+
The 1 analysts with a live target average $1.00 for Virax Biolabs Group Limited Ordinary Shares over the next 12 months, ranging from a $1.00 high to a $1.00 low.
Is VRAX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover VRAX?+
1 analysts have an active rating on Virax Biolabs Group Limited Ordinary Shares, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering VRAX?+
Among analysts who currently cover VRAX, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #276). Their current call is Buy with a $1.00 target.
What is Virax Biolabs Group Limited Ordinary Shares's projected EPS for next quarter?+
The consensus estimate is $-1.75 per share (range $-1.75 – $-1.75) across 1 analysts. Full-year EPS is projected at $-6.00, rising to $-6.00 the following year.
How much revenue is Virax Biolabs Group Limited Ordinary Shares expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $4.0K, growing to $4.0K next year.
Have analysts been upgrading or downgrading VRAX lately?+
As of Aug, 1 of 1 firms rate VRAX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
